logo-loader
Paradigm Biopharmaceuticals Ltd

Paradigm's drug developments sees growing market opportunities

Paul Rennie, chief executive for Paradigm Biopharmaceuticals, speaks with Proactive Investors.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: $1.44

Market: ASX
Market Cap: $276.78 m
Follow

Watch

e-Therapeutics’ Barlow hails deals with Novo Nordisk and ‘top five pharma...

Ray Barlow, chief executive of e-Therapeutics (LON:ETX), talks to Proactive’s Andrew Scott about the company’s unique approach to drug discovery, which uses computational techniques to find potential breakthrough new treatments. He also provided some insight into recent tie-ups with Denmark’s...

4 days, 16 hours ago

2 min read

;